Monte Rosa Therapeutics, Inc. (GLUE) stock
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07−0.09 (-0.98%)
Close on Nov 17, 2026Market cap $773.79MP/E –Yield –
Monte Rosa Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Monte Rosa Therapeutics's price to sales ratio was 30.6× on Nov 11, 2026, against 5.5× a year earlier. Over the last 3 years it ranged from 1.6× to 213.3×, with a median of 27.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 30.6× | +25.3 |
| 2025 | Dec 31, 2025 | 5.3× | −23.1 |
| 2024 | Dec 31, 2024 | 28.4× | – |
See a number that looks wrong?